NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
14 trialsNCT07392060 2026-02-06
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Shanghai Jiatan Pharmatech Co., Ltd
Phase 3 Not yet recruiting
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT07371897 2026-01-28
SHINE
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07362186 2026-01-23
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
LaNova Medicines Limited
Phase 3 Not yet recruiting
NCT07340515 2026-01-14
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Shandong Cancer Hospital and Institute
Phase 3 Recruiting
NCT07111832 2025-12-18
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07251582 2025-11-26
LungTime-C02
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07177794 2025-09-17
EC-CRT-008
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06228079 2025-07-04
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Eye & ENT Hospital of Fudan University
Phase 3 Recruiting
NCT06235203 2025-06-03
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Eye & ENT Hospital of Fudan University
Phase 3 Recruiting
NCT06977893 2025-05-18
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
First Affiliated Hospital of Zhejiang University
Phase 3 Recruiting
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting